Zacks: Brokerages Anticipate Atara Biotherapeutics Inc (ATRA) to Announce -$1.18 EPS

Wall Street analysts expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings per share of ($1.18) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.17) and the lowest is ($1.18). Atara Biotherapeutics posted earnings of ($1.02) per share in the same quarter last year, which would suggest a negative year over year growth rate of 15.7%. The business is scheduled to announce its next earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($4.58) per share for the current fiscal year, with EPS estimates ranging from ($4.59) to ($4.58). For the next fiscal year, analysts anticipate that the company will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.17).

Several equities analysts recently issued reports on ATRA shares. BidaskClub lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 27th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $45.00 price objective on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Hold” and a consensus target price of $47.80.

Shares of ATRA stock opened at $36.42 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of -9.11 and a beta of 2.54. Atara Biotherapeutics has a 52-week low of $12.65 and a 52-week high of $54.45.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $38.00, for a total value of $296,400.00. Following the completion of the sale, the chief executive officer now directly owns 812,613 shares in the company, valued at $30,879,294. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Joe Newell sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $35.78, for a total transaction of $357,800.00. Following the completion of the sale, the insider now owns 41,858 shares of the company’s stock, valued at $1,497,679.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 93,575 shares of company stock worth $3,633,158. 10.60% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Atara Biotherapeutics in the first quarter valued at approximately $107,000. Great West Life Assurance Co. Can boosted its stake in Atara Biotherapeutics by 100.1% in the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 1,655 shares in the last quarter. Bank of Montreal Can acquired a new stake in Atara Biotherapeutics in the second quarter valued at approximately $180,000. Principal Financial Group Inc. acquired a new stake in Atara Biotherapeutics in the first quarter valued at approximately $214,000. Finally, Highland Private Wealth Management acquired a new stake in Atara Biotherapeutics in the second quarter valued at approximately $202,000.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: What is a closed-end mutual fund (CEF)?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply